Canada’s initiative to construct a $267 million medical countermeasures laboratory in Winnipeg is seen as a crucial move to prevent future pandemics. However, experts caution that the facility will encounter significant challenges related to securing long-term funding, staffing, and governance.
The federal government recently awarded a $10.2 million contract for the design of the facility, which is scheduled to open in 2033 next to Winnipeg’s National Microbiology Laboratory (NML). While the lab is designed to address a critical need for testing early-stage vaccines, therapeutics, and diagnostic tools, health researchers stress that sustained investments in human resources are essential for its success.
Dr. Joanne Liu, a physician and professor at McGill University’s School of Population and Global Health, emphasized the importance of having skilled personnel to establish the lab as a world-class center. She highlighted the necessity of aligning actions with the goal of developing effective countermeasures.
The planned laboratory aims to enhance capacity for preclinical trials, including laboratory and animal testing, within Canada’s research and development framework. This dedicated space would enable scientists to conduct preliminary testing on small vaccine batches before advancing to clinical trials. Currently, space constraints at the NML sometimes force the repurposing of facilities for preclinical tests on highly infectious pathogens like Ebola.
Industry and academic partners may utilize the lab spaces, subject to the necessary agreements and vetting processes, according to NML’s chief operating officer, Steven Guercio. Addressing existing limitations, Keith Fowke, scientific director at the Canadian Institutes of Health Research’s infections facility in Winnipeg, noted that the absence of local cleanrooms hinders Canadian researchers from progressing vaccine discoveries to early human safety trials.
Experts advocate for expanding Canada’s capabilities in this area, a topic that has been under discussion for over a decade. Gary Kobinger, a former NML scientist involved in developing the world’s first successful Ebola vaccine, stressed the importance of committing to long-term funding to advance research products over the next decade.
Ensuring sustained funding during non-crisis periods is crucial, as noted by McGill’s Liu. She underscored the need for continuous investment in pandemic research, even when not in the spotlight, to support comprehensive virus research and countermeasure development.
Recognizing red tape and governance risks, Kobinger cautioned against solely government-run operations at the countermeasures lab. He cited past challenges in Canada’s management of the Ebola vaccine development, emphasizing the importance of effective governance to avoid funding obstacles and ensure operational success.
While PHAC highlighted significant federal investments to strengthen Canada’s life sciences sector, Kobinger stressed the need to learn from past experiences to prevent delays in operationalizing critical facilities. He emphasized the pivotal role of leadership in aligning efforts and navigating bureaucratic hurdles for successful project implementation.